GPKOW

Summary

GPKOW (G-patch domain and KOW motifs, HGNC:30677) is a protein-coding gene on chromosome Xp11.23, encoding G-patch domain and KOW motifs-containing protein (Q92917). RNA-binding protein involved in pre-mRNA splicing. It is a common-essential gene (DepMap: required in 97.7% of cancer cell lines).

This gene encodes a putative RNA-binding protein containing G-patch and KOW (Kyprides, Ouzounis, Woese) domains. The encoded protein interacts directly with protein kinase A and protein kinase X and is also found associated with the spliceosome.

Source: NCBI Gene 27238 — RefSeq curated summary.

At a glance

• Gene–disease (curated): syndromic disease (Strong, GenCC) — +1 more curated relationship
• Clinical variants (ClinVar): 136 total
• Phenotypes (HPO): 24
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 97.7% of screened cell lines (common-essential)
• MANE Select transcript: NM_015698

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30677
Approved symbol	GPKOW
Name	G-patch domain and KOW motifs
Location	Xp11.23
Locus type	gene with protein product
Status	Approved
Aliases	T54, GPATC5, GPATCH5, Spp2, Mos2
Ensembl gene	ENSG00000068394
Ensembl biotype	protein_coding
OMIM	301003
Entrez	27238

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 6 protein_coding

ENST00000156109, ENST00000916257, ENST00000916258, ENST00000916259, ENST00000961387, ENST00000961388

RefSeq mRNA: 1 — MANE Select: NM_015698 NM_015698

CCDS: CCDS35251

Canonical transcript exons

ENST00000156109 — 11 exons

Exon	Start	End
ENSE00000670287	49122398	49122522
ENSE00000670295	49117597	49117810
ENSE00001094859	49122622	49122776
ENSE00001150601	49123547	49123735
ENSE00001305620	49116221	49116323
ENSE00001317932	49119705	49119814
ENSE00001325789	49117030	49117162
ENSE00001601302	49115726	49115795
ENSE00001701291	49115891	49116014
ENSE00001731716	49113853	49113938
ENSE00001756911	49113407	49113755

Expression profiles

Bgee: expression breadth ubiquitous, 281 present calls, max score 91.19.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.6981 / max 89.2489, expressed in 1799 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
199238	10.3581	1794
199239	0.9102	610
199237	0.4298	163

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
paraflocculus	UBERON:0005351	91.19	gold quality
gastrocnemius	UBERON:0001388	90.32	gold quality
muscle of leg	UBERON:0001383	90.09	gold quality
frontal pole	UBERON:0002795	89.71	gold quality
middle frontal gyrus	UBERON:0002702	88.91	gold quality
hindlimb stylopod muscle	UBERON:0004252	88.57	gold quality
mucosa of transverse colon	UBERON:0004991	88.57	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	88.31	gold quality
granulocyte	CL:0000094	88.24	gold quality
muscle organ	UBERON:0001630	88.13	gold quality
popliteal artery	UBERON:0002250	87.99	gold quality
tibial artery	UBERON:0007610	87.98	gold quality
triceps brachii	UBERON:0001509	87.89	gold quality
tendon of biceps brachii	UBERON:0008188	87.71	gold quality
spinal cord	UBERON:0002240	87.67	gold quality
right frontal lobe	UBERON:0002810	87.63	gold quality
aorta	UBERON:0000947	87.42	gold quality
cingulate cortex	UBERON:0003027	87.27	gold quality
anterior cingulate cortex	UBERON:0009835	87.23	gold quality
medial globus pallidus	UBERON:0002477	87.18	gold quality
gluteal muscle	UBERON:0002000	87.13	gold quality
substantia nigra	UBERON:0002038	86.84	gold quality
thoracic aorta	UBERON:0001515	86.78	gold quality
ascending aorta	UBERON:0001496	86.72	gold quality
descending thoracic aorta	UBERON:0002345	86.68	gold quality
apex of heart	UBERON:0002098	86.57	gold quality
nucleus accumbens	UBERON:0001882	86.54	gold quality
lower esophagus muscularis layer	UBERON:0035833	86.52	gold quality
lower esophagus	UBERON:0013473	86.50	gold quality
hypothalamus	UBERON:0001898	86.46	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.60

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

14 targeting GPKOW, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-1260A	99.61	66.67	1098
HSA-MIR-1260B	99.61	66.67	1098
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-203A-3P	99.49	70.56	2806
HSA-MIR-6839-3P	99.39	68.86	1301
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-6780B-3P	99.13	67.18	622
HSA-MIR-637	97.91	64.05	1517
HSA-MIR-1224-3P	97.24	65.92	851
HSA-MIR-1288-3P	96.86	66.95	536
HSA-MIR-5579-5P	96.32	68.54	730
HSA-MIR-3130-3P	94.98	66.97	574

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 97.7% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 2)

• Data show that G patch domain and KOW motifs protein (GPKOW )interacted directly with the DEAH-box protein 16 (DHX16/hPRP2) and with RNA. (PMID:25296192)
• GPKOW c.331+5G>A variant disrupts normal splicing of its pre-mRNAs and causes male-lethal microcephaly with intrauterine growth restriction. (PMID:28612833)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	gpkow	ENSDARG00000029612
mus_musculus	Gpkow	ENSMUSG00000031148
rattus_norvegicus	Gpkow	ENSRNOG00000022939
drosophila_melanogaster	CG10324	FBGN0038454
caenorhabditis_elegans		WBGENE00011237

Protein

Protein identifiers

G-patch domain and KOW motifs-containing protein — Q92917 (reviewed: Q92917)

Alternative names: G-patch domain-containing protein 5, Protein MOS2 homolog, Protein T54

All UniProt accessions (1): Q92917

UniProt curated annotations — full annotation on UniProt →

Function. RNA-binding protein involved in pre-mRNA splicing. As a component of the minor spliceosome, involved in the splicing of U12-type introns in pre-mRNAs.

Subunit / interactions. Component of the minor spliceosome, which splices U12-type introns. Interacts with PRKX. Interacts with DHX16. Interacts with PRKACB.

Subcellular location. Nucleus.

Post-translational modifications. Phosphorylation regulates its ability to bind RNA.

Similarity. Belongs to the MOS2 family.

RefSeq proteins (1): NP_056513* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000467	G_patch_dom	Domain
IPR005824	KOW	Domain
IPR014722	Rib_uL2_dom2	Homologous_superfamily
IPR026822	Spp2/MOS2_G-patch	Domain
IPR041993	GPKOW_KOW1	Domain
IPR041994	GPKOW_KOW2	Domain
IPR045166	Spp2-like	Family

Pfam: PF00467, PF12656, PF25088

UniProt features (33 total): modified residue 9, compositionally biased region 5, mutagenesis site 4, domain 3, region of interest 3, helix 2, turn 2, initiator methionine 1, chain 1, cross-link 1, sequence conflict 1, strand 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
7DVQ	ELECTRON MICROSCOPY	2.89
7QTT	ELECTRON MICROSCOPY	3.1
8CH6	ELECTRON MICROSCOPY	5.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q92917-F1	70.15	0.25

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (10): 2, 27, 35, 42, 115, 216, 316, 471, 473, 5

Mutagenesis-validated functional residues (4):

Position	Phenotype
27	reduced phosphorylation. significant loss of phosphorylation and increased rna-binding; when associated with a-316.
176–177	significant loss of interaction with dhx16. no loss of pre-mrna splicing activity. able to suppress the splicing defect
259–260	no loss of interaction with dhx16. reduced pre-mrna splicing activity. decreased ability to suppress the splicing defect
316	reduced phosphorylation. significant loss of phosphorylation and increased rna-binding; when associated with a-27.

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-72163	mRNA Splicing - Major Pathway
R-HSA-9918481	Dengue Virus-Host Interactions

MSigDB gene sets: 228 (showing top): GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GOCC_SECRETORY_GRANULE, REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION, GNF2_HPN, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, MODULE_120, WANG_LMO4_TARGETS_DN, ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN, REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA, GNF2_LCAT, HSIAO_LIVER_SPECIFIC_GENES, GOBP_RNA_SPLICING, REACTOME_MRNA_SPLICING, GNF2_HPX, MODULE_88

GO Biological Process (3): mRNA splicing, via spliceosome (GO:0000398), mRNA processing (GO:0006397), RNA splicing (GO:0008380)

GO Molecular Function (3): RNA binding (GO:0003723), nucleic acid binding (GO:0003676), protein binding (GO:0005515)

GO Cellular Component (3): nucleus (GO:0005634), nucleoplasm (GO:0005654), spliceosomal complex (GO:0005681)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
mRNA Splicing	1
Dengue Virus Infection	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA processing	2
binding	2
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	1
mRNA processing	1
mRNA metabolic process	1
nucleic acid binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
nuclear protein-containing complex	1
ribonucleoprotein complex	1

Protein interactions and networks

STRING

1474 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GPKOW	SCN11A	Q9UI33	925
GPKOW	MX2	P20592	922
GPKOW	NDUFAF3	Q9BU61	909
GPKOW	HAO1	Q9UJM8	798
GPKOW	BHLHE40	O14503	772
GPKOW	VASP	P50552	772
GPKOW	CARD16	Q5EG05	728
GPKOW	ZNF174	Q15697	727
GPKOW	SERF1A	O75920	724
GPKOW	DHX16	O60231	709
GPKOW	ALB	P02768	689
GPKOW	C1S	P09871	622
GPKOW	DHX38	Q92620	621
GPKOW	SFMBT1	Q9UHJ3	560
GPKOW	PLAUR	Q03405	507

IntAct

235 interactions, top by confidence:

A	B	Type	Score
BUD13	GPKOW	psi-mi:“MI:0915”(physical association)	0.940
GPKOW	BUD13	psi-mi:“MI:0915”(physical association)	0.940
HEXIM1	CCNT1	psi-mi:“MI:0914”(association)	0.930
MED17	MED19	psi-mi:“MI:0914”(association)	0.840
GPKOW	DHX16	psi-mi:“MI:0914”(association)	0.820
GPKOW	TCEA2	psi-mi:“MI:0915”(physical association)	0.780
GOLGA2	GPKOW	psi-mi:“MI:0915”(physical association)	0.780
GPKOW	TRAF2	psi-mi:“MI:0915”(physical association)	0.780
TRAF2	GPKOW	psi-mi:“MI:0915”(physical association)	0.780
TCEA2	GPKOW	psi-mi:“MI:0915”(physical association)	0.780
ROPN1	GPKOW	psi-mi:“MI:0915”(physical association)	0.720
GPKOW	ROPN1	psi-mi:“MI:0915”(physical association)	0.720
TRIM23	GPKOW	psi-mi:“MI:0915”(physical association)	0.670
GPKOW	TRIM23	psi-mi:“MI:0915”(physical association)	0.670

BioGRID (170): GPKOW (Two-hybrid), GPKOW (Two-hybrid), GPKOW (Two-hybrid), GPKOW (Two-hybrid), GPKOW (Two-hybrid), ROPN1 (Two-hybrid), BUD13 (Two-hybrid), CCDC57 (Two-hybrid), DHX16 (Affinity Capture-Western), DHX16 (Reconstituted Complex), GPKOW (Affinity Capture-Western), GPKOW (Affinity Capture-MS), GPKOW (Two-hybrid), TLN1 (Co-fractionation), GPKOW (Affinity Capture-MS)

ESM2 similar proteins: A1XD93, A1XD95, A1XD97, A4UMC5, A7SBN6, B3DJT0, B3MPC0, B3N8L3, B4G7U3, B4HWD7, B4JCG4, B4KH32, B4M9F7, B4NYQ2, B4Q8A7, C0HAV3, E7EXT2, F7AEX0, O75940, Q06AK6, Q17CQ8, Q28H71, Q29NF3, Q29RR5, Q4QQU6, Q56A08, Q5PPF5, Q5RET3, Q5U2X2, Q5U2Y6, Q5U4Z3, Q5ZMQ9, Q66HA5, Q6DEY1, Q6DI35, Q6K687, Q6NU07, Q7PYU6, Q7SXW2, Q8BGT7

Diamond homologs: Q21924, Q4P9X4, Q4WP02, Q56A08, Q5B4R9, Q6BJ73, Q6NU07, Q753C4, Q90X38, Q92917, Q9C801, O43031, Q02521, Q52E73, Q6FMB1, Q6CUA3, A0JMV4, A4IGK4, B2GV05, P52756, P70501, P98175, Q1RMU5, Q55D16, Q6DDU9, Q91YE7, Q99KG3, Q9NW75, Q9ZVU5, Q7TQC7

SIGNOR signaling

8 interactions.

A	Effect	B	Mechanism
GPKOW	“up-regulates quantity”	DHX16	binding
PRKACB	“up-regulates activity”	GPKOW	phosphorylation
PRKACA	“up-regulates activity”	GPKOW	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

136 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	58
Likely benign	8
Benign	5

Top pathogenic / likely-pathogenic (0)

SpliceAI

1733 predictions. Top by Δscore:

Variant	Effect	Δscore
X:49113751:CCCAC:C	acceptor_gain	1.0000
X:49113752:CCAC:C	acceptor_gain	1.0000
X:49113752:CCACC:C	acceptor_gain	1.0000
X:49113753:CAC:C	acceptor_gain	1.0000
X:49113753:CACC:C	acceptor_gain	1.0000
X:49113756:C:CC	acceptor_gain	1.0000
X:49113762:C:CT	acceptor_gain	1.0000
X:49113763:A:T	acceptor_gain	1.0000
X:49113847:ACT:A	donor_loss	1.0000
X:49113848:CTC:C	donor_loss	1.0000
X:49113849:TCAC:T	donor_loss	1.0000
X:49113850:CACC:C	donor_loss	1.0000
X:49113851:A:AC	donor_gain	1.0000
X:49113851:AC:A	donor_gain	1.0000
X:49113851:ACCCT:A	donor_loss	1.0000
X:49113852:C:CC	donor_gain	1.0000
X:49113852:CC:C	donor_gain	1.0000
X:49113852:CCCTT:C	donor_gain	1.0000
X:49113934:CAGGC:C	acceptor_gain	1.0000
X:49113937:GCCTA:G	acceptor_loss	1.0000
X:49113938:CCTA:C	acceptor_loss	1.0000
X:49113939:C:CC	acceptor_gain	1.0000
X:49113939:CT:C	acceptor_loss	1.0000
X:49113940:T:G	acceptor_loss	1.0000
X:49115792:TCAT:T	acceptor_gain	1.0000
X:49115793:CATC:C	acceptor_gain	1.0000
X:49115795:TCTG:T	acceptor_loss	1.0000
X:49115796:C:T	acceptor_loss	1.0000
X:49115797:T:C	acceptor_loss	1.0000
X:49115885:TCCCA:T	donor_loss	1.0000

AlphaMissense

3071 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:49119742:A:G	W177R	0.986
X:49119742:A:T	W177R	0.986
X:49113657:G:C	C465W	0.981
X:49115756:A:G	C394R	0.978
X:49119768:C:T	G168E	0.977
X:49119740:C:A	W177C	0.976
X:49119740:C:G	W177C	0.976
X:49119756:A:G	L172P	0.976
X:49113658:C:T	C465Y	0.975
X:49115962:A:G	W357R	0.975
X:49115962:A:T	W357R	0.975
X:49119762:G:T	A170D	0.974
X:49115960:C:A	W357C	0.973
X:49115960:C:G	W357C	0.973
X:49119741:C:G	W177S	0.973
X:49119772:A:C	Y167D	0.971
X:49115754:A:C	C394W	0.969
X:49122741:A:G	I71T	0.969
X:49119753:C:G	R173P	0.968
X:49119769:C:A	G168W	0.968
X:49113659:A:G	C465R	0.967
X:49119756:A:T	L172Q	0.966
X:49115788:A:T	I383N	0.965
X:49119763:C:G	A170P	0.965
X:49115937:C:G	R365P	0.963
X:49119746:C:A	M175I	0.963
X:49119746:C:G	M175I	0.963
X:49119746:C:T	M175I	0.963
X:49113908:A:T	V414D	0.961
X:49117125:A:T	V273D	0.961

dbSNP variants (sampled 300 via entrez): RS1000175311 (X:49124527 C>T), RS1000227699 (X:49125024 C>G), RS1001347209 (X:49117943 G>A), RS1001796924 (X:49118441 T>C,G), RS1002293475 (X:49119600 T>A,C), RS1003349929 (X:49121864 G>A), RS1003708523 (X:49121623 A>C,G), RS1004420134 (X:49114073 G>A,T), RS1005881654 (X:49116541 C>G,T), RS1006267559 (X:49119415 T>A,C), RS1006471418 (X:49118935 A>G), RS1007919100 (X:49112992 G>T), RS1007971636 (X:49113430 C>G), RS1008282724 (X:49123527 T>C), RS1008484154 (X:49122885 A>G)

Disease associations

OMIM: gene MIM:301003 | disease phenotypes: MIM:306990

GenCC curated gene-disease

Disease	Classification	Inheritance
syndromic disease	Strong	X-linked
holoprosencephaly-hypokinesia-congenital contractures syndrome	Moderate	X-linked

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
holoprosencephaly-hypokinesia-congenital contractures syndrome	Moderate	XL

Mondo (2): holoprosencephaly-hypokinesia-congenital contractures syndrome (MONDO:0010610), syndromic disease (MONDO:0002254)

Orphanet (1): Lethal intrauterine growth restriction-cortical malformation-congenital contractures syndrome (Orphanet:2570)

HPO phenotypes

24 total (24 of 24 shown, HPO-id order):

HPO	Term
HP:0000252	Microcephaly
HP:0000340	Sloping forehead
HP:0000347	Micrognathia
HP:0000369	Low-set ears
HP:0000470	Short neck
HP:0000490	Deeply set eye
HP:0000581	Blepharophimosis
HP:0001181	Adducted thumb
HP:0001360	Holoprosencephaly
HP:0001376	Limitation of joint mobility
HP:0001511	Intrauterine growth retardation
HP:0001558	Decreased fetal movement
HP:0002103	Abnormal pleura morphology
HP:0002120	Cerebral cortical atrophy
HP:0002324	Hydranencephaly
HP:0002828	Multiple joint contractures
HP:0006703	Aplasia/Hypoplasia of the lungs
HP:0007360	Aplasia/Hypoplasia of the cerebellum
HP:0007370	Aplasia/Hypoplasia of the corpus callosum
HP:0007477	Abnormal dermatoglyphics
HP:0008678	Renal hypoplasia/aplasia
HP:0010662	Abnormal diencephalon morphology
HP:0100490	Camptodactyly of finger
HP:0100625	Enlarged thorax

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D013577	Syndrome	C23.550.288.500
C564409	Holoprosencephaly with Fetal Akinesia-Hypokinesia Sequence (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067442 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

42 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases abundance, increases expression, decreases expression	2
Arsenic	decreases expression, increases abundance, affects methylation	2
Benzo(a)pyrene	increases methylation, affects methylation	2
aristolochic acid I	increases expression	1
FR900359	increases phosphorylation	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, decreases methylation	1
deoxynivalenol	increases expression	1
terbufos	decreases methylation	1
cobaltous chloride	decreases expression	1
manganese chloride	increases abundance, decreases expression	1
4-aminophenylarsenoxide	affects binding, decreases reaction	1
abrine	increases expression	1
Sunitinib	decreases expression	1
Arsenic Trioxide	affects binding, decreases reaction	1
Fulvestrant	affects cotreatment, decreases methylation	1
Atrazine	decreases expression	1
Azacitidine	increases expression	1
Benztropine	decreases expression, affects cotreatment	1
Caffeine	affects phosphorylation	1
Cuprizone	affects cotreatment, decreases expression	1
Bucladesine	affects cotreatment, increases expression	1
Doxorubicin	increases expression	1
Fonofos	decreases methylation	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Estradiol	increases expression, affects cotreatment	1
Hydrogen Peroxide	affects expression	1
Ivermectin	decreases expression	1
Lead	decreases expression	1
Manganese	decreases expression, increases abundance	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651497	Binding	Binding affinity to human GPKOW incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

1 cell lines: 1 induced pluripotent stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_YZ89	KICRi002-A-2	Induced pluripotent stem cell	Male

Clinical trials (associated diseases)

25 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00027456	PHASE2	COMPLETED	Leptin to Treat Severe Insulin Resistance - Pilot Study
NCT00213447	Not specified	COMPLETED	T Cell Response in Hypersensitivity Syndrome
NCT02240888	Not specified	COMPLETED	Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response
NCT02526082	Not specified	ACTIVE_NOT_RECRUITING	Long-term Follow-up of the Helsinki Businessmen Study
NCT02637518	Not specified	UNKNOWN	Comprehensive Validation of Frailty Assessment Tools in Older Adults in Different Clinical and Social Settings
NCT02971072	Not specified	COMPLETED	Neurophysiology of Weakness and Exercise in Rotator Cuff Tendinopathy
NCT02974569	Not specified	COMPLETED	Improving Symptom Self-management in Adolescents & Young Adults With Cancer
NCT03265561	Not specified	COMPLETED	Spinal Infection Management With Structural Allograft
NCT04190342	Not specified	COMPLETED	Effects of a Traditional Chinese Exercise Program on Symptom Cluster in Breast Cancer Patients
NCT04874584	Not specified	COMPLETED	Culturally Tailored Nurse Coaching Study for Cancer Symptom Management
NCT04909489	Not specified	UNKNOWN	PDR and SKYD of Dyslipidemia’s Characteristics From the Oxidative Stress Enhancement Caused by Inhibition of Serine Metabolic Pathway
NCT05218122	Not specified	UNKNOWN	Characteristics of LKDS and PBSS of KOA Based on the Enhancement of Inflammatory Response by TGF-β/Smad Pathway Inhibited
NCT05266118	Not specified	COMPLETED	Patient Reported Symptoms the First Week After Intensive Care Unit Discharge and up to Hospital Discharge
NCT05321966	Not specified	COMPLETED	The Effect of Video Training on Symptom Burden Patients Undergoing Hemodialysis Treatment
NCT05818748	Not specified	UNKNOWN	Effect Of Virtual Reality Distraction on Symptom Control and Anxiety in Children With Leukemia
NCT05837988	Not specified	UNKNOWN	Construction of Symptom Network in Maintenance Hemodialysis Patients
NCT06143436	Not specified	UNKNOWN	TCM Constitution, Pattern Types, and Disease Factors in Primary Lung Cancer.
NCT06222008	Not specified	UNKNOWN	Study on Symptom Clusters During Chemotherapy in Ovarian Cancer Patients With Different Chinese Medicine Constitution
NCT06412107	Not specified	COMPLETED	Somatic Acupressure for Symptom Cluster Management in Breast Cancer Survivors
NCT06847360	Not specified	RECRUITING	Home-based Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for IBS Pain
NCT07281300	Not specified	RECRUITING	Mindfulness-Oriented Respiratory Distress Symptom Intervention for Lung Cancer
NCT07315672	Not specified	RECRUITING	Acupressure for Cough in Lung Cancer Survivors
NCT07479654	Not specified	NOT_YET_RECRUITING	AI-Enabled Frailty Risk Prediction in Adult Congenital Heart Disease
NCT07495358	Not specified	NOT_YET_RECRUITING	Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cancer Undergoing Chemotherapy
NCT07576114	Not specified	RECRUITING	Comparison of Gluteal Muscle Activation and Core Strengthening in Dead Butt Syndrome Syndrome